News
02-22-2016, 03:14 AM
Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).
More... (http://www.news-medical.net/news/20160222/Romosozumab-for-postmenopausal-women-with-osteoporosis-meets-co-primary-endpoints-in-Phase-3-study.aspx)
More... (http://www.news-medical.net/news/20160222/Romosozumab-for-postmenopausal-women-with-osteoporosis-meets-co-primary-endpoints-in-Phase-3-study.aspx)